Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.37 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.30 |
| ▸ | CRAT | P43155 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953473 | 0.84 | PLA2G2C (0.35) | PLA2G2C | |
| Hydrochloric Acid SCHEMBL3954249 | 0.81 | PLA2G2C (0.34) | PLA2G2CENPEPCRAT | |
| SCHEMBL3960297 | 0.81 | PLA2G2C (0.34) | PLA2G2C | |
| SCHEMBL3954061 | 0.80 | PLA2G2C (0.36) | PLA2G2C | |
| SCHEMBL3951444 | 0.80 | PLA2G2C (0.33) | PLA2G2C | |
| Hydrochloric Acid SCHEMBL3959400 | 0.80 | PLA2G2C (0.33) | PLA2G2C | |
| SCHEMBL3962063 | 0.79 | PLA2G2C (0.35) | PLA2G2C | |
| SCHEMBL3954358 | 0.79 | PLA2G2C (0.35) | PLA2G2C | |
| SCHEMBL3949838 | 0.78 | PLA2G2C (0.34) | PLA2G2C | |
| Trifluoroacetic Acid SCHEMBL3951541 | 0.78 | PLA2G2C (0.32) | PLA2G2CENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | claimed |
| WO-2009033079-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | claimed |
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. | 2009-03-26 | — | — | US | disclosed |
| WO-2009033079-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082464-A1 | EXTERNALLY MASKED NEOPENTYL SULFONYL ESTER CYCLIZATION RELEASE PRODRUGS OF ACAMPROSATE, COMPOSITIONS THEREOF, AND METHODS OF USE | AASDHPPT, ADSL, NAPEPLD | PLA2G2C 3229/4885ENPEP 419/4885CRAT 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.